Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02166658 : A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

1. Adult patients (? 18 years of age)

2. Histologically or cytologically confirmed stage IV lung or breast cancer with
progressive or recurrent brain metastases

3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

4. Prior external beam radiotherapy (WBRT or SRS) of BM Patients suffering from small
cell lung cancer (SCLC) who have been treated with chemotherapy and prophylactic
cranial radiotherapy may be also enrolled.

5. At least one two-dimensional measurable lesion on brain MRI

6. Life expectancy at least 3 months

7. Females of childbearing potential (FCBP) must have a negative pregnancy test within 7
days of the first application of study treatment and must agree to use effective
contraceptive birth control measures (Pearl Index < 1) during the course of the
Trial. A female subject is considered to be of childbearing potential unless she is
age ? 50 years and naturally amenorrhoeic for ? 2 year, or unless she is surgically

8. Males must agree to use effective contraception (Pearl Index < 1) during the course
of the trial and for at least 6 months after last administration of study medication
cabazitaxel. In addition males must agree to prevent contact with the ejaculate by
another person throughout study treatment.

Exclusion Criteria:

1. Prior chemotherapy or targeted therapy (e.g. erlotinib, bevacizumab) for brain

2. Any chemotherapy or targeted tumor therapy within two weeks of study inclusion or

3. Any antihormonal tumor treatment within two weeks of study inclusion or concomitantly

4. Time interval to prior external beam radiotherapy less than 2 weeks

5. Suspected or known leptomeningeal disease

6. Peripheral neuropathy ? grade 2

7. Inadequate organ and bone marrow function as evidenced by:

- Absolute neutrophil count (ANC) < 1.5 x 10*9/L;

- Hemoglobin < 10.0 g/dL;

- Platelet count < 100 x 10*9/L;

- Total bilirubin ? 1 x upper limit of normal (ULN);

- AST/GOT and/or ALT/GPT ? 1.5 x ULN;

- Serum creatinine > 1.5 x ULN. If creatinine 1.0 - 1.5 x ULN; creatinine
clearance has to be calculated according to Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula and patients with creatinine clearance < 60
mL/min must be excluded

8. Other inadequate organ function according to investigator's discretion

9. History of hypersensitivity reaction to docetaxel

10. History of hypersensitivity reaction to polysorbate 80 containing drugs

11. Uncontrolled severe illness or medical condition (including uncontrolled diabetes

12. Concurrent or planned treatment with strong inhibitors or strong inducers of
cytochrome P450 3A4/5 (a one week washout period is necessary for patients who are
already on these treatments; see also Section 10 and Appendix 3 and 4; dexamethasone
is allowed)

13. Recently received or planned vaccination against yellow fever during study treatment

14. Pregnant or breast feeding females

15. Participation in any other clinical trial or treatment with any experimental drug
within 28 day before enrolment to the study or during study participation until the
end of treatment visit

16. Previous or concurrent tumor other than underlying tumor disease (breast or lung
cancer) with the exception of cervical cancer in situ, adequately treated basal cell
carcinoma or squamous cell carcinoma of the skin, superficial bladder tumors (Ta,Tis,
and T1) or any curatively treated tumors > 5 years prior to enrolment
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557